Northern Trust Corp Raises Stock Holdings in Organogenesis Holdings Inc. (NASDAQ:ORGO)

Northern Trust Corp increased its stake in shares of Organogenesis Holdings Inc. (NASDAQ:ORGO) by 2.9% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 616,089 shares of the company’s stock after purchasing an additional 17,196 shares during the quarter. Northern Trust Corp owned approximately 0.49% of Organogenesis worth $1,971,000 as of its most recent SEC filing.

A number of other hedge funds have also recently made changes to their positions in the stock. Dimensional Fund Advisors LP lifted its stake in shares of Organogenesis by 18.9% during the 4th quarter. Dimensional Fund Advisors LP now owns 2,789,265 shares of the company’s stock worth $8,925,000 after purchasing an additional 442,772 shares during the last quarter. Renaissance Technologies LLC lifted its stake in shares of Organogenesis by 31.3% during the 4th quarter. Renaissance Technologies LLC now owns 1,073,500 shares of the company’s stock worth $3,435,000 after purchasing an additional 255,600 shares during the last quarter. Norges Bank purchased a new stake in shares of Organogenesis during the 4th quarter worth $1,543,000. Bank of New York Mellon Corp raised its stake in Organogenesis by 35.5% in the fourth quarter. Bank of New York Mellon Corp now owns 418,820 shares of the company’s stock valued at $1,340,000 after buying an additional 109,762 shares during the last quarter. Finally, JPMorgan Chase & Co. raised its stake in Organogenesis by 36.4% in the fourth quarter. JPMorgan Chase & Co. now owns 280,997 shares of the company’s stock valued at $899,000 after buying an additional 75,054 shares during the last quarter. 49.57% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at Organogenesis

In other news, Director Michael Joseph Driscoll sold 25,000 shares of the firm’s stock in a transaction dated Tuesday, March 4th. The stock was sold at an average price of $5.10, for a total value of $127,500.00. Following the completion of the transaction, the director now directly owns 166,879 shares in the company, valued at $851,082.90. This trade represents a 13.03% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Company insiders own 36.90% of the company’s stock.

Wall Street Analyst Weigh In

Separately, Morgan Stanley increased their price target on Organogenesis from $4.00 to $6.00 and gave the company an “equal weight” rating in a research note on Wednesday, March 5th.

Organogenesis Trading Down 2.4%

Organogenesis stock opened at $2.90 on Monday. The stock has a 50-day moving average of $4.21 and a two-hundred day moving average of $3.92. The company has a debt-to-equity ratio of 0.21, a quick ratio of 2.74 and a current ratio of 3.09. Organogenesis Holdings Inc. has a one year low of $2.28 and a one year high of $6.71. The stock has a market cap of $367.88 million, a PE ratio of -48.33 and a beta of 1.85.

Organogenesis (NASDAQ:ORGO) last released its quarterly earnings results on Thursday, May 8th. The company reported ($0.13) EPS for the quarter, missing analysts’ consensus estimates of $0.04 by ($0.17). Organogenesis had a negative net margin of 1.62% and a negative return on equity of 2.69%. The business had revenue of $86.69 million during the quarter, compared to analysts’ expectations of $90.77 million. On average, research analysts anticipate that Organogenesis Holdings Inc. will post -0.07 EPS for the current fiscal year.

Organogenesis Company Profile

Organogenesis Holdings Inc, a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage.